National MS Society: Large Study of Exposure to DMTs During Pregnancy Finds Some Associations With Low Birth Weight With No Other Notable Adverse Outcomes
January 15, 2025
January 15, 2025
NEW YORK, Jan. 15 (TNSjou) -- The National Multiple Sclerosis Society issued the following news:
A study of pregnancy outcomes in 3,722 women with MS found no association between exposure to disease-modifying therapies (DMTs) and spontaneous abortions, premature births or major congenital defects. MS itself, and exposure to fingolimod, siponimod, natalizumab, ocrelizumab, and rituximab, was associated with low birth weight. Severe infections were rare, and associated with fumarates . . .
A study of pregnancy outcomes in 3,722 women with MS found no association between exposure to disease-modifying therapies (DMTs) and spontaneous abortions, premature births or major congenital defects. MS itself, and exposure to fingolimod, siponimod, natalizumab, ocrelizumab, and rituximab, was associated with low birth weight. Severe infections were rare, and associated with fumarates . . .